Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective

Journal of Medicinal Chemistry

Volumn 60, Issue 17, 2017, Pages 7213-7232

  Bongarzone, Salvatore ^a   Savickas, Vilius ^a   Luzi, Federico ^a   Gee, Antony D ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR ANTAGONIST; AMYLOID BETA PROTEIN; METHYLGLYOXAL; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN S 100; QUINOLINIC ACID; REACTIVE OXYGEN METABOLITE; ADVANCED GLYCATION END PRODUCT; ISOPROTEIN; MOLECULAR LIBRARY;

APOPTOSIS; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; DIABETES MELLITUS; HUMAN; INTRACELLULAR SIGNALING; LIGAND BINDING; NERVE DEGENERATION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN TARGETING; REVIEW; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; NEURODEGENERATIVE DISEASES; PHARMACOLOGY; PROCEDURES; PROTEIN DOMAIN; THERAPEUTIC USE;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DRUG DISCOVERY; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEURODEGENERATIVE DISEASES; PROTEIN DOMAINS; PROTEIN ISOFORMS; REACTIVE OXYGEN SPECIES; SMALL MOLECULE LIBRARIES;

EID: 85029469841     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.7b00058     Document Type: Review

References (144)

1. Vistoli, G.; De Maddis, D.; Cipak, A.; Zarkovic, N.; Carini, M.; Aldini, G. Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation Free Radical Res. 2013, 47 (Sup 1) 3-27 10.3109/10715762.2013.815348
2. Adrover, M.; Marino, L.; Sanchis, P.; Pauwels, K.; Kraan, Y.; Lebrun, P.; Vilanova, B.; Munoz, F.; Broersen, K.; Donoso, J. Mechanistic insights in glycation-induced protein aggregation Biomacromolecules 2014, 15, 3449-3462 10.1021/bm501077j
3. Sajithlal, G. B.; Chithra, P.; Chandrakasan, G. Advanced glycation end products induce crosslinking of collagen in vitro Biochim. Biophys. Acta, Mol. Basis Dis. 1998, 1407, 215-224 10.1016/S0925-4439(98)00043-X
4. Nenna, A.; Spadaccio, C.; Lusini, M.; Ulianich, L.; Chello, M.; Nappi, F. Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications Recent Pat. Cardiovasc. Drug Discovery 2015, 10, 10-33 10.2174/1574890110666151104120039
5. Li, J.; Liu, D.; Sun, L.; Lu, Y.; Zhang, Z. Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective J. Neurol. Sci. 2012, 317, 1-5 10.1016/j.jns.2012.02.018
6. Rocken, C.; Kientsch-Engel, R.; Mansfeld, S.; Stix, B.; Stubenrauch, K.; Weigle, B.; Buhling, F.; Schwan, M.; Saeger, W. Advanced glycation end products and receptor for advanced glycation end products in AA amyloidosis Am. J. Pathol. 2003, 162, 1213-1220 10.1016/S0002-9440(10)63917-X
7. Sparvero, L. J.; Asafu-Adjei, D.; Kang, R.; Tang, D.; Amin, N.; Im, J.; Rutledge, R.; Lin, B.; Amoscato, A. A.; Zeh, H. J.; Lotze, M. T. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation J. Transl. Med. 2009, 7, 17 10.1186/1479-5876-7-17
8. Ramasamy, R.; Vannucci, S. J.; Yan, S. S. D.; Herold, K.; Yan, S. F.; Schmidt, A. M. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation Glycobiology 2005, 15, 16R-28R 10.1093/glycob/cwi053
9. Ray, R.; Juranek, J. K.; Rai, V. RAGE axis in neuroinflammation, neurodegeneration and its emerging role in the pathogenesis of amyotrophic lateral sclerosis Neurosci. Biobehav. Rev. 2016, 62, 48-55 10.1016/j.neubiorev.2015.12.006
10. Neeper, M.; Schmidt, A. M.; Brett, J.; Yan, S. D.; Wang, F.; Pan, Y. C.; Elliston, K.; Stern, D.; Shaw, A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins J. Biol. Chem. 1992, 267, 14998-15004
11. Cheng, C.; Tsuneyama, K.; Kominami, R.; Shinohara, H.; Sakurai, S.; Yonekura, H.; Watanabe, T.; Takano, Y.; Yamamoto, H.; Yamamoto, Y. Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs Mod. Pathol. 2005, 18, 1385-1396 10.1038/modpathol.3800450
12. Tanji, N.; Markowitz, G. S.; Fu, C.; Kislinger, T.; Taguchi, A.; Pischetsrieder, M.; Stern, D.; Schmidt, A. M.; D'Agati, V. D. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease J. Am. Soc. Nephrol. 2000, 11, 1656-1666
13. Falcone, C.; Emanuele, E.; D'Angelo, A.; Buzzi, M. P.; Belvito, C.; Cuccia, M.; Geroldi, D. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men Arterioscler., Thromb., Vasc. Biol. 2005, 25, 1032-1037 10.1161/01.ATV.0000160342.20342.00
14. Emanuele, E.; D'Angelo, A.; Tomaino, C.; Binetti, G.; Ghidoni, R.; Politi, P.; Bernardi, L.; Maletta, R.; Bruni, A. C.; Geroldi, D. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia Arch. Neurol. 2005, 62, 1734-1736 10.1001/archneur.62.11.1734
15. Riehl, A.; Nemeth, J.; Angel, P.; Hess, J. The receptor RAGE: Bridging inflammation and cancer Cell Commun. Signaling 2009, 7, 12 10.1186/1478-811X-7-12
16. Nasser, M. W.; Wani, N. A.; Ahirwar, D. K.; Powell, C. A.; Ravi, J.; Elbaz, M.; Zhao, H.; Padilla, L.; Zhang, X.; Shilo, K.; Ostrowski, M.; Shapiro, C.; Carson, W. E., 3rd; Ganju, R. K. RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment Cancer Res. 2015, 75, 974-985 10.1158/0008-5472.CAN-14-2161
17. Deane, R.; Singh, I.; Sagare, A. P.; Bell, R. D.; Ross, N. T.; LaRue, B.; Love, R.; Perry, S.; Paquette, N.; Deane, R. J.; Thiyagarajan, M.; Zarcone, T.; Fritz, G.; Friedman, A. E.; Miller, B. L.; Zlokovic, B. V. A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease J. Clin. Invest. 2012, 122, 1377-1392 10.1172/JCI58642
18. Cary, B. P.; Brooks, A. F.; Fawaz, M. V.; Drake, L. R.; Desmond, T. J.; Sherman, P.; Quesada, C. A.; Scott, P. J. Synthesis and Evaluation of [(18)F]RAGER: A First Generation Small-Molecule PET Radioligand Targeting the Receptor for Advanced Glycation Endproducts ACS Chem. Neurosci. 2016, 7, 391-398 10.1021/acschemneuro.5b00319
19. Galasko, D.; Bell, J.; Mancuso, J. Y.; Kupiec, J. W.; Sabbagh, M. N.; van Dyck, C.; Thomas, R. G.; Aisen, P. S. Alzheimer's Disease Cooperative, S. Clinical trial of an inhibitor of RAGE-Abeta interactions in Alzheimer disease Neurology 2014, 82, 1536-1542 10.1212/WNL.0000000000000364
20. UniProtKB-Q15109 (RAGE-HUMAN); UniProt, 2017; http://www.uniprot.org/uniprot/Q15109 (accessed April 6, 2017).
21. Yatime, L.; Andersen, G. R. Structural insights into the oligomerization mode of the human receptor for advanced glycation end-products FEBS J. 2013, 280, 6556-6568 10.1111/febs.12556
22. Xue, J.; Rai, V.; Singer, D.; Chabierski, S.; Xie, J.; Reverdatto, S.; Burz, D. S.; Schmidt, A. M.; Hoffmann, R.; Shekhtman, A. Advanced glycation end product recognition by the receptor for AGEs Structure 2011, 19, 722-732 10.1016/j.str.2011.02.013
23. Koch, M.; Chitayat, S.; Dattilo, B. M.; Schiefner, A.; Diez, J.; Chazin, W. J.; Fritz, G. Structural basis for ligand recognition and activation of RAGE Structure 2010, 18, 1342-1352 10.1016/j.str.2010.05.017
24. Dattilo, B. M.; Fritz, G.; Leclerc, E.; vander Kooi, C. W.; Heizmann, C. W.; Chazin, W. J. The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units Biochemistry 2007, 46, 6957-6970 10.1021/bi7003735
25. Sturchler, E.; Galichet, A.; Weibel, M.; Leclerc, E.; Heizmann, C. W. Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity J. Neurosci. 2008, 28, 5149-5158 10.1523/JNEUROSCI.4878-07.2008
26. Xue, J.; Ray, R.; Singer, D.; Bohme, D.; Burz, D. S.; Rai, V.; Hoffmann, R.; Shekhtman, A. The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal-derived AGEs Biochemistry 2014, 53, 3327-3335 10.1021/bi500046t
27. Hori, O.; Brett, J.; Slattery, T.; Cao, R.; Zhang, J.; Chen, J. X.; Nagashima, M.; Lundh, E. R.; Vijay, S.; Nitecki, D. et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system J. Biol. Chem. 1995, 270, 25752-25761 10.1074/jbc.270.43.25752
28. Xie, J.; Reverdatto, S.; Frolov, A.; Hoffmann, R.; Burz, D. S.; Shekhtman, A. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE) J. Biol. Chem. 2008, 283, 27255-27269 10.1074/jbc.M801622200
29. Xie, J.; Burz, D. S.; He, W.; Bronstein, I. B.; Lednev, I.; Shekhtman, A. Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches J. Biol. Chem. 2007, 282, 4218-4231 10.1074/jbc.M608888200
30. Zong, H.; Madden, A.; Ward, M.; Mooney, M. H.; Elliott, C. T.; Stitt, A. W. Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction J. Biol. Chem. 2010, 285, 23137-23146 10.1074/jbc.M110.133827
31. Xu, D.; Young, J. H.; Krahn, J. M.; Song, D.; Corbett, K. D.; Chazin, W. J.; Pedersen, L. C.; Esko, J. D. Stable RAGE-heparan sulfate complexes are essential for signal transduction ACS Chem. Biol. 2013, 8, 1611-1620 10.1021/cb4001553
32. Rodriguez Gonzalez-Moro, J. M.; de Lucas Ramos, P.; Izquierdo Alonso, J. L.; Lopez-Muniz Ballesteros, B.; Anton Diaz, E.; Ribera, X.; Martin, A. Impact of COPD severity on physical disability and daily living activities: EDIP-EPOC I and EDIP-EPOC II studies Int. J. Clin. Pract. 2009, 63, 742-750 10.1111/j.1742-1241.2009.02040.x
33. Sakaguchi, M.; Murata, H.; Yamamoto, K.; Ono, T.; Sakaguchi, Y.; Motoyama, A.; Hibino, T.; Kataoka, K.; Huh, N. H. TIRAP, an adaptor protein for TLR2/4, transduces a signal from RAGE phosphorylated upon ligand binding PLoS One 2011, 6, e23132 10.1371/journal.pone.0023132
34. Rai, V.; Maldonado, A. Y.; Burz, D. S.; Reverdatto, S.; Schmidt, A. M.; Shekhtman, A. Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of C-terminal rage (ctRAGE) and its binding to mDia1 J. Biol. Chem. 2012, 287, 5133-5144 10.1074/jbc.M111.277731
35. Manigrasso, M. B.; Pan, J.; Rai, V.; Zhang, J.; Reverdatto, S.; Quadri, N.; DeVita, R. J.; Ramasamy, R.; Shekhtman, A.; Schmidt, A. M. Small Molecule Inhibition of Ligand-Stimulated RAGE-DIAPH1 Signal Transduction Sci. Rep. 2016, 6, 22450 10.1038/srep22450
36. Ishihara, K.; Tsutsumi, K.; Kawane, S.; Nakajima, M.; Kasaoka, T. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site FEBS Lett. 2003, 550, 107-113 10.1016/S0014-5793(03)00846-9
37. Hudson, B. I.; Kalea, A. Z.; Del Mar Arriero, M.; Harja, E.; Boulanger, E.; D'Agati, V.; Schmidt, A. M. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42 J. Biol. Chem. 2008, 283, 34457-34468 10.1074/jbc.M801465200
38. Huttunen, H. J.; Fages, C.; Rauvala, H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways J. Biol. Chem. 1999, 274, 19919-19924 10.1074/jbc.274.28.19919
39. Harja, E.; Bu, D. X.; Hudson, B. I.; Chang, J. S.; Shen, X.; Hallam, K.; Kalea, A. Z.; Lu, Y.; Rosario, R. H.; Oruganti, S.; Nikolla, Z.; Belov, D.; Lalla, E.; Ramasamy, R.; Yan, S. F.; Schmidt, A. M. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice J. Clin. Invest. 2008, 118, 183-194 10.1172/JCI32703
40. Jules, J.; Maiguel, D.; Hudson, B. I. Alternative splicing of the RAGE cytoplasmic domain regulates cell signaling and function PLoS One 2013, 8, e78267 10.1371/journal.pone.0078267
41. Zhang, L.; Bukulin, M.; Kojro, E.; Roth, A.; Metz, V. V.; Fahrenholz, F.; Nawroth, P. P.; Bierhaus, A.; Postina, R. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases J. Biol. Chem. 2008, 283, 35507-35516 10.1074/jbc.M806948200
42. Pan, H.; He, L.; Wang, B.; Niu, W. The relationship between RAGE gene four common polymorphisms and breast cancer risk in northeastern Han Chinese Sci. Rep. 2015, 4, 4355 10.1038/srep04355
43. Cai, W.; Li, J.; Xu, J. X.; Liu, Y.; Zhang, W.; Xiao, J. R.; Zhu, L. Y.; Liu, J. Y. Association of 2184AG Polymorphism in the RAGE Gene with Diabetic Nephropathy in Chinese Patients with Type 2 Diabetes J. Diabetes Res. 2015, 2015, 310237 10.1155/2015/310237
44. Hudson, B. I.; Carter, A. M.; Harja, E.; Kalea, A. Z.; Arriero, M.; Yang, H.; Grant, P. J.; Schmidt, A. M. Identification, classification, and expression of RAGE gene splice variants FASEB J. 2008, 22, 1572-1580 10.1096/fj.07-9909com
45. Ding, Q.; Keller, J. N. Evaluation of rage isoforms, ligands, and signaling in the brain Biochim. Biophys. Acta, Mol. Cell Res. 2005, 1746, 18-27 10.1016/j.bbamcr.2005.08.006
46. Hong, Y.; Shen, C.; Yin, Q.; Sun, M.; Ma, Y.; Liu, X. Effects of RAGE-Specific Inhibitor FPS-ZM1 on Amyloid-beta Metabolism and AGEs-Induced Inflammation and Oxidative Stress in Rat Hippocampus Neurochem. Res. 2016, 41, 1192-1199 10.1007/s11064-015-1814-8
47. Kaji, Y.; Usui, T.; Ishida, S.; Yamashiro, K.; Moore, T. C.; Moore, J.; Yamamoto, Y.; Yamamoto, H.; Adamis, A. P. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products Invest. Ophthalmol. Visual Sci. 2007, 48, 858-865 10.1167/iovs.06-0495
48. Takeuchi, A.; Yamamoto, Y.; Munesue, S.; Harashima, A.; Watanabe, T.; Yonekura, H.; Yamamoto, H.; Tsuchiya, H. Low molecular weight heparin suppresses receptor for advanced glycation end products-mediated expression of malignant phenotype in human fibrosarcoma cells Cancer Sci. 2013, 104, 740-749 10.1111/cas.12133
49. Li, Y.; Wu, R.; Tian, Y.; Yu, M.; Tang, Y.; Cheng, H.; Tian, Z. RAGE/NF-kappaB signaling mediates lipopolysaccharide induced acute lung injury in neonate rat model Int. J. Clin. Exp. Med. 2015, 8, 13371-13376
50. Lue, L. F.; Walker, D. G.; Brachova, L.; Beach, T. G.; Rogers, J.; Schmidt, A. M.; Stern, D. M.; Yan, S. D. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: Identification of a cellular activation mechanism Exp. Neurol. 2001, 171, 29-45 10.1006/exnr.2001.7732
51. Huang, J. S.; Guh, J. Y.; Chen, H. C.; Hung, W. C.; Lai, Y. H.; Chuang, L. Y. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells J. Cell. Biochem. 2001, 81, 102-113 10.1002/1097-4644(20010401)81:1<102::AID-JCB1027>3.0.CO;2-Y
52. Reynolds, P. R.; Kasteler, S. D.; Cosio, M. G.; Sturrock, A.; Huecksteadt, T.; Hoidal, J. R. RAGE: developmental expression and positive feedback regulation by Egr-1 during cigarette smoke exposure in pulmonary epithelial cells Am. J. Physiol.: Lung Cell. Mol. Physiol. 2008, 294, L1094-1101 10.1152/ajplung.00318.2007
53. Kosaka, T.; Fukui, R.; Matsui, M.; Kurosaka, Y.; Nishimura, H.; Tanabe, M.; Takakura, Y.; Iwai, K.; Waki, T.; Fujita, T. RAGE, receptor of advanced glycation endoproducts, negatively regulates chondrocytes differentiation PLoS One 2014, 9, e108819 10.1371/journal.pone.0108819
54. Yonekura, H.; Yamamoto, Y.; Sakurai, S.; Petrova, R. G.; Abedin, M. J.; Li, H.; Yasui, K.; Takeuchi, M.; Makita, Z.; Takasawa, S.; Okamoto, H.; Watanabe, T.; Yamamoto, H. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury Biochem. J. 2003, 370, 1097-1109 10.1042/bj20021371
55. Kalea, A. Z.; Schmidt, A. M.; Hudson, B. I. RAGE: a novel biological and genetic marker for vascular disease Clin. Sci. 2009, 116, 621-637 10.1042/CS20080494
56. Geroldi, D.; Falcone, C.; Emanuele, E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target Curr. Med. Chem. 2006, 13, 1971-1978 10.2174/092986706777585013
57. Yamagishi, S.; Adachi, H.; Nakamura, K.; Matsui, T.; Jinnouchi, Y.; Takenaka, K.; Takeuchi, M.; Enomoto, M.; Furuki, K.; Hino, A.; Shigeto, Y.; Imaizumi, T. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects Metab., Clin. Exp. 2006, 55, 1227-1231 10.1016/j.metabol.2006.05.007
58. Cho, H. J.; Son, S. M.; Jin, S. M.; Hong, H. S.; Shin, D. H.; Kim, S. J.; Huh, K.; Mook-Jung, I. RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model FASEB J. 2009, 23, 2639-2649 10.1096/fj.08-126383
59. Santilli, F.; Vazzana, N.; Bucciarelli, L. G.; Davi, G. Soluble forms of RAGE in human diseases: clinical and therapeutical implications Curr. Med. Chem. 2009, 16, 940-952 10.2174/092986709787581888
60. Zhang, L.; Postina, R.; Wang, Y. Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer's disease Cell. Mol. Life Sci. 2009, 66, 3923-3935 10.1007/s00018-009-0121-4
61. Park, H.; Boyington, J. C. The 1.5 A crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding J. Biol. Chem. 2010, 285, 40762-40770 10.1074/jbc.M110.169276
62. Ostendorp, T.; Leclerc, E.; Galichet, A.; Koch, M.; Demling, N.; Weigle, B.; Heizmann, C. W.; Kroneck, P. M.; Fritz, G. Structural and functional insights into RAGE activation by multimeric S100B EMBO J. 2007, 26, 3868-3878 10.1038/sj.emboj.7601805
63. Huttunen, H. J.; Fages, C.; Kuja-Panula, J.; Ridley, A. J.; Rauvala, H. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis Cancer Res. 2002, 62, 4805-4811
64. Botos, I.; Segal, D. M.; Davies, D. R. The Structural Biology of Toll-like Receptors Structure 2011, 19, 447-459 10.1016/j.str.2011.02.004
65. Sinha, P.; Okoro, C.; Foell, D.; Freeze, H. H.; Ostrand-Rosenberg, S.; Srikrishna, G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells J. Immunol. 2008, 181, 4666-4675 10.4049/jimmunol.181.7.4666
66. Rothermundt, M.; Peters, M.; Prehn, J. H.; Arolt, V. S100B in brain damage and neurodegeneration Microsc. Res. Tech. 2003, 60, 614-632 10.1002/jemt.10303
67. Schlueter, C.; Weber, H.; Meyer, B.; Rogalla, P.; Roser, K.; Hauke, S.; Bullerdiek, J. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule Am. J. Pathol. 2005, 166, 1259-1263 10.1016/S0002-9440(10)62344-9
68. Gao, T. L.; Yuan, X. T.; Yang, D.; Dai, H. L.; Wang, W. J.; Peng, X.; Shao, H. J.; Jin, Z. F.; Fu, Z. J. Expression of HMGB1 and RAGE in rat and human brains after traumatic brain injury J. Trauma Acute Care Surg. 2012, 72, 643-649 10.1097/TA.0b013e31823c54a6
69. Jara, N.; Leal, M. J.; Bunout, D.; Hirsch, S.; Barrera, G.; Leiva, L.; de la Maza, M. P. Dietary intake increases serum levels of carboxymethil-lysine (CML) in diabetic patients Nutr. Hosp. 2012, 27, 1272-1278 10.3305/nh.2012.27.4.5861
70. Berlanga, J.; Cibrian, D.; Guillen, I.; Freyre, F.; Alba, J. S.; Lopez-Saura, P.; Merino, N.; Aldama, A.; Quintela, A. M.; Triana, M. E.; Montequin, J. F.; Ajamieh, H.; Urquiza, D.; Ahmed, N.; Thornalley, P. J. Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds Clin. Sci. 2005, 109, 83-95 10.1042/CS20050026
71. Leclerc, E.; Fritz, G.; Vetter, S. W.; Heizmann, C. W. Binding of S100 proteins to RAGE: an update Biochim. Biophys. Acta, Mol. Cell Res. 2009, 1793, 993-1007 10.1016/j.bbamcr.2008.11.016
72. Leclerc, E.; Fritz, G.; Weibel, M.; Heizmann, C. W.; Galichet, A. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains J. Biol. Chem. 2007, 282, 31317-31331 10.1074/jbc.M703951200
73. Onyeagucha, B. C.; Mercado-Pimentel, M. E.; Hutchison, J.; Flemington, E. K.; Nelson, M. A. S100P/RAGE signaling regulates microRNA-155 expression via AP-1 activation in colon cancer Exp. Cell Res. 2013, 319, 2081-2090 10.1016/j.yexcr.2013.05.009
74. Hofmann, M. A.; Drury, S.; Fu, C.; Qu, W.; Taguchi, A.; Lu, Y.; Avila, C.; Kambham, N.; Bierhaus, A.; Nawroth, P.; Neurath, M. F.; Slattery, T.; Beach, D.; McClary, J.; Nagashima, M.; Morser, J.; Stern, D.; Schmidt, A. M. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides Cell 1999, 97, 889-901 10.1016/S0092-8674(00)80801-6
75. Xue, J.; Manigrasso, M.; Scalabrin, M.; Rai, V.; Reverdatto, S.; Burz, D. S.; Fabris, D.; Schmidt, A. M.; Shekhtman, A. Change in the Molecular Dimension of a RAGE-Ligand Complex Triggers RAGE Signaling Structure 2016, 24, 1509-1522 10.1016/j.str.2016.06.021
76. Mercado-Pimentel, M. E.; Onyeagucha, B. C.; Li, Q.; Pimentel, A. C.; Jandova, J.; Nelson, M. A. The S100P/RAGE signaling pathway regulates expression of microRNA-21 in colon cancer cells FEBS Lett. 2015, 589, 2388-2393 10.1016/j.febslet.2015.07.010
77. Penumutchu, S. R.; Chou, R. H.; Yu, C. Structural insights into calcium-bound S100P and the V domain of the RAGE complex PLoS One 2014, 9, e103947 10.1371/journal.pone.0103947
78. Arumugam, T.; Simeone, D. M.; Schmidt, A. M.; Logsdon, C. D. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE) J. Biol. Chem. 2004, 279, 5059-5065 10.1074/jbc.M310124200
79. Matsumoto, S.; Yoshida, T.; Murata, H.; Harada, S.; Fujita, N.; Nakamura, S.; Yamamoto, Y.; Watanabe, T.; Yonekura, H.; Yamamoto, H.; Ohkubo, T.; Kobayashi, Y. Solution structure of the variable-type domain of the receptor for advanced glycation end products: new insight into AGE-RAGE interaction Biochemistry 2008, 47, 12299-12311 10.1021/bi800910v
80. Kim, S.; Kim, S. Y.; Pribis, J. P.; Lotze, M.; Mollen, K. P.; Shapiro, R.; Loughran, P.; Scott, M. J.; Billiar, T. R. Signaling of high mobility group box 1 (HMGB1) through toll-like receptor 4 in macrophages requires CD14 Mol. Med. 2013, 19, 88-98 10.2119/molmed.2012.00306
81. Orlova, V. V.; Choi, E. Y.; Xie, C.; Chavakis, E.; Bierhaus, A.; Ihanus, E.; Ballantyne, C. M.; Gahmberg, C. G.; Bianchi, M. E.; Nawroth, P. P.; Chavakis, T. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin EMBO J. 2007, 26, 1129-1139 10.1038/sj.emboj.7601552
82. Yan, S. D.; Chen, X.; Fu, J.; Chen, M.; Zhu, H.; Roher, A.; Slattery, T.; Zhao, L.; Nagashima, M.; Morser, J.; Migheli, A.; Nawroth, P.; Stern, D.; Schmidt, A. M. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease Nature 1996, 382, 685-691 10.1038/382685a0
83. Chaney, M. O.; Stine, W. B.; Kokjohn, T. A.; Kuo, Y. M.; Esh, C.; Rahman, A.; Luehrs, D. C.; Schmidt, A. M.; Stern, D.; Yan, S. D.; Roher, A. E. RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling Biochim. Biophys. Acta, Mol. Basis Dis. 2005, 1741, 199-205 10.1016/j.bbadis.2005.03.014
84. Deane, R.; Du Yan, S.; Submamaryan, R. K.; LaRue, B.; Jovanovic, S.; Hogg, E.; Welch, D.; Manness, L.; Lin, C.; Yu, J.; Zhu, H.; Ghiso, J.; Frangione, B.; Stern, A.; Schmidt, A. M.; Armstrong, D. L.; Arnold, B.; Liliensiek, B.; Nawroth, P.; Hofman, F.; Kindy, M.; Stern, D.; Zlokovic, B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain Nat. Med. 2003, 9, 907-913 10.1038/nm890
85. Yan, S. D.; Stern, D.; Kane, M. D.; Kuo, Y. M.; Lampert, H. C.; Roher, A. E. RAGE-Abeta interactions in the pathophysiology of Alzheimer's disease Restor. Neurol. Neurosci. 1998, 12, 167-173
86. Lugo-Huitron, R.; Ugalde Muniz, P.; Pineda, B.; Pedraza-Chaverri, J.; Rios, C.; Perez-de la Cruz, V. Quinolinic acid: an endogenous neurotoxin with multiple targets Oxid. Med. Cell. Longevity 2013, 2013, 104024 10.1155/2013/104024
87. Serratos, I. N.; Castellanos, P.; Pastor, N.; Millán-Pacheco, C.; Rembao, D.; Pérez-Montfort, R.; Cabrera, N.; Reyes-Espinosa, F.; Díaz-Garrido, P.; López-Macay, A.; Martínez-Flores, K.; López-Reyes, A.; Sánchez-García, A.; Cuevas, E.; Santamaria, A. Modeling the Interaction between Quinolinate and the Receptor for Advanced Glycation End Products (RAGE): Relevance for Early Neuropathological Processes PLoS One 2015, 10, e0120221 10.1371/journal.pone.0120221
88. Cuevas, E.; Lantz, S.; Newport, G.; Divine, B.; Wu, Q.; Paule, M. G.; Tobon-Velasco, J. C.; Ali, S. F.; Santamaria, A. On the early toxic effect of quinolinic acid: involvement of RAGE Neurosci. Lett. 2010, 474, 74-78 10.1016/j.neulet.2010.03.007
89. Yamamoto, K.; Murata, H.; Putranto, E. W.; Kataoka, K.; Motoyama, A.; Hibino, T.; Inoue, Y.; Sakaguchi, M.; Huh, N. H. DOCK7 is a critical regulator of the RAGE-Cdc42 signaling axis that induces formation of dendritic pseudopodia in human cancer cells Oncol. Rep. 2013, 29, 1073-1079 10.3892/or.2012.2191
90. Lin, Y. N.; Bhuwania, R.; Gromova, K.; Failla, A. V.; Lange, T.; Riecken, K.; Linder, S.; Kneussel, M.; Izbicki, J. R.; Windhorst, S. Drosophila homologue of Diaphanous 1 (DIAPH1) controls the metastatic potential of colon cancer cells by regulating microtubule-dependent adhesion Oncotarget 2015, 6, 18577-18589 10.18632/oncotarget.4094
91. Chen, S. C.; Guh, J. Y.; Hwang, C. C.; Chiou, S. J.; Lin, T. D.; Ko, Y. M.; Huang, J. S.; Yang, Y. L.; Chuang, L. Y. Advanced glycation end-products activate extracellular signal-regulated kinase via the oxidative stress-EGF receptor pathway in renal fibroblasts J. Cell. Biochem. 2010, 109, 38-48 10.1002/jcb.22376
92. Zhou, Y.; Johnson, J. L.; Cerione, R. A.; Erickson, J. W. Prenylation and membrane localization of Cdc42 are essential for activation by DOCK7 Biochemistry 2013, 52, 4354-4363 10.1021/bi301688g
93. Brett, J.; Schmidt, A. M.; Yan, S. D.; Zou, Y. S.; Weidman, E.; Pinsky, D.; Nowygrod, R.; Neeper, M.; Przysiecki, C.; Shaw, A. et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues Am. J. Pathol. 1993, 143, 1699-1712
94. Wendt, T.; Harja, E.; Bucciarelli, L.; Qu, W.; Lu, Y.; Rong, L. L.; Jenkins, D. G.; Stein, G.; Schmidt, A. M.; Yan, S. F. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes Atherosclerosis 2006, 185, 70-77 10.1016/j.atherosclerosis.2005.06.013
95. Ahmed, N. Advanced glycation endproducts - role in pathology of diabetic complications Diabetes Res. Clin. Pract. 2005, 67, 3-21 10.1016/j.diabres.2004.09.004
96. Uchida, T.; Shirasawa, M.; Ware, L. B.; Kojima, K.; Hata, Y.; Makita, K.; Mednick, G.; Matthay, Z. A.; Matthay, M. A. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury Am. J. Respir. Crit. Care Med. 2006, 173, 1008-1015 10.1164/rccm.200509-1477OC
97. Buckley, S. T.; Ehrhardt, C. The receptor for advanced glycation end products (RAGE) and the lung J. Biomed. Biotechnol. 2010, 2010, 917108 10.1155/2010/917108
98. Zeng, S.; Cataldegirmen, G.; Feirt, N.; Ippagunta, N.; Dun, H.; Wu, Q.; Yan, L.; Rong, L. L.; Yan, S. F.; Schmidt, A. M.; Emond, J. C. RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-KB Hepatology 2004, 40, 284a-285a
99. Liu, Y.; Liang, C.; Liu, X.; Liao, B.; Pan, X.; Ren, Y.; Fan, M.; Li, M.; He, Z.; Wu, J.; Wu, Z. AGEs increased migration and inflammatory responses of adventitial fibroblasts via RAGE, MAPK and NF-kappaB pathways Atherosclerosis 2010, 208, 34-42 10.1016/j.atherosclerosis.2009.06.007
100. Yeh, C. H.; Sturgis, L.; Haidacher, J.; Zhang, X. N.; Sherwood, S. J.; Bjercke, R. J.; Juhasz, O.; Crow, M. T.; Tilton, R. G.; Denner, L. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion Diabetes 2001, 50, 1495-1504 10.2337/diabetes.50.6.1495
101. Perkins, N. D. Integrating cell-signalling pathways with NF-kappaB and IKK function Nat. Rev. Mol. Cell Biol. 2007, 8, 49-62 10.1038/nrm2083
102. Chen, C. H.; Zhou, W.; Liu, S.; Deng, Y.; Cai, F.; Tone, M.; Tone, Y.; Tong, Y.; Song, W. Increased NF-kappaB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease Int. J. Neuropsychopharmacol. 2012, 15, 77-90 10.1017/S1461145711000149
103. Bianchi, R.; Giambanco, I.; Donato, R. S100B/RAGE-dependent activation of microglia via NF-kappaB and AP-1 Co-regulation of COX-2 expression by S100B, IL-1beta and TNF-alpha Neurobiol. Aging 2010, 31, 665-677 10.1016/j.neurobiolaging.2008.05.017
104. Chen, X.; Zhang, L.; Zhang, I. Y.; Liang, J.; Wang, H.; Ouyang, M.; Wu, S.; da Fonseca, A. C.; Weng, L.; Yamamoto, Y.; Yamamoto, H.; Natarajan, R.; Badie, B. RAGE expression in tumor-associated macrophages promotes angiogenesis in glioma Cancer Res. 2014, 74, 7285-7297 10.1158/0008-5472.CAN-14-1240
105. Fuentes, M. K.; Nigavekar, S. S.; Arumugam, T.; Logsdon, C. D.; Schmidt, A. M.; Park, J. C.; Huang, E. H. RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways Dis. Colon Rectum 2007, 50, 1230-1240 10.1007/s10350-006-0850-5
106. Kislinger, T.; Tanji, N.; Wendt, T.; Qu, W.; Lu, Y.; Ferran, L. J., Jr.; Taguchi, A.; Olson, K.; Bucciarelli, L.; Goova, M.; Hofmann, M. A.; Cataldegirmen, G.; D'Agati, V.; Pischetsrieder, M.; Stern, D. M.; Schmidt, A. M. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice Arterioscler., Thromb., Vasc. Biol. 2001, 21, 905-910 10.1161/01.ATV.21.6.905
107. Ramasamy, R.; Yan, S. F.; Schmidt, A. M. Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications Ann. N. Y. Acad. Sci. 2011, 1243, 88-102 10.1111/j.1749-6632.2011.06320.x
108. Coughlan, M. T.; Thorburn, D. R.; Penfold, S. A.; Laskowski, A.; Harcourt, B. E.; Sourris, K. C.; Tan, A. L.; Fukami, K.; Thallas-Bonke, V.; Nawroth, P. P.; Brownlee, M.; Bierhaus, A.; Cooper, M. E.; Forbes, J. M. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes J. Am. Soc. Nephrol. 2009, 20, 742-752 10.1681/ASN.2008050514
109. Aleshin, A.; Ananthakrishnan, R.; Li, Q.; Rosario, R.; Lu, Y.; Qu, W.; Song, F.; Bakr, S.; Szabolcs, M.; D'Agati, V.; Liu, R.; Homma, S.; Schmidt, A. M.; Yan, S. F.; Ramasamy, R. RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model Am. J. Physiol.: Heart Circ. Physiol. 2008, 294, H1823-1832 10.1152/ajpheart.01210.2007
110. Chung, J.; An, S. H.; Kang, S. W.; Kwon, K. Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting RAGE Signaling in Diabetic Atherosclerosis PLoS One 2016, 11, e0147839 10.1371/journal.pone.0147839
111. Hudson, B. I.; Bucciarelli, L. G.; Wendt, T.; Sakaguchi, T.; Lalla, E.; Qu, W.; Lu, Y.; Lee, L.; Stern, D. M.; Naka, Y.; Ramasamy, R.; Yan, S. D.; Yan, S. F.; D'Agati, V.; Schmidt, A. M. Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders Arch. Biochem. Biophys. 2003, 419, 80-88 10.1016/j.abb.2003.08.030
112. Deane, R. J. Is RAGE still a therapeutic target for Alzheimer's disease? Future Med. Chem. 2012, 4, 915-925 10.4155/fmc.12.51
113. Miller, M. C.; Tavares, R.; Johanson, C. E.; Hovanesian, V.; Donahue, J. E.; Gonzalez, L.; Silverberg, G. D.; Stopa, E. G. Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease Brain Res. 2008, 1230, 273-280 10.1016/j.brainres.2008.06.124
114. Sasaki, N.; Toki, S.; Chowei, H.; Saito, T.; Nakano, N.; Hayashi, Y.; Takeuchi, M.; Makita, Z. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease Brain Res. 2001, 888, 256-262 10.1016/S0006-8993(00)03075-4
115. Jeynes, B.; Provias, J. Evidence for altered LRP/RAGE expression in Alzheimer lesion pathogenesis Curr. Alzheimer Res. 2008, 5, 432-437 10.2174/156720508785908937
116. Donahue, J. E.; Flaherty, S. L.; Johanson, C. E.; Duncan, J. A., 3rd; Silverberg, G. D.; Miller, M. C.; Tavares, R.; Yang, W.; Wu, Q.; Sabo, E.; Hovanesian, V.; Stopa, E. G. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease Acta Neuropathol. 2006, 112, 405-415 10.1007/s00401-006-0115-3
117. Li, X. H.; Lv, B. L.; Xie, J. Z.; Liu, J.; Zhou, X. W.; Wang, J. Z. AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation Neurobiol. Aging 2012, 33, 1400-1410 10.1016/j.neurobiolaging.2011.02.003
118. Guglielmotto, M.; Aragno, M.; Tamagno, E.; Vercellinatto, I.; Visentin, S.; Medana, C.; Catalano, M. G.; Smith, M. A.; Perry, G.; Danni, O.; Boccuzzi, G.; Tabaton, M. AGEs/RAGE complex upregulates BACE1 via NF-kappaB pathway activation Neurobiol. Aging 2012, 33, 196.e13-196.327 10.1016/j.neurobiolaging.2010.05.026
119. Kumar, A.; Singh, A.; Ekavali A review on Alzheimer's disease pathophysiology and its management: an update Pharmacol. Rep. 2015, 67, 195-203 10.1016/j.pharep.2014.09.004
120. Takuma, K.; Fang, F.; Zhang, W.; Yan, S.; Fukuzaki, E.; Du, H.; Sosunov, A.; McKhann, G.; Funatsu, Y.; Nakamichi, N.; Nagai, T.; Mizoguchi, H.; Ibi, D.; Hori, O.; Ogawa, S.; Stern, D. M.; Yamada, K.; Yan, S. S. RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 20021-20026 10.1073/pnas.0905686106
121. Burstein, A. H.; Grimes, I.; Galasko, D. R.; Aisen, P. S.; Sabbagh, M.; Mjalli, A. M. Effect of TTP488 in patients with mild to moderate Alzheimer's disease BMC Neurol. 2014, 14, 12 10.1186/1471-2377-14-12
122. Sabbagh, M. N.; Agro, A.; Bell, J.; Aisen, P. S.; Schweizer, E.; Galasko, D. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease Alzheimer Dis. Assoc. Disord. 2011, 25, 206-212 10.1097/WAD.0b013e318204b550
123. Lee, Y. S.; Kim, H.; Kim, Y. H.; Roh, E. J.; Han, H.; Shin, K. J. Synthesis and structure-activity relationships of tri-substituted thiazoles as RAGE antagonists for the treatment of Alzheimer's disease Bioorg. Med. Chem. Lett. 2012, 22, 7555-7561 10.1016/j.bmcl.2012.10.022
124. Han, Y. T.; Choi, G. I.; Son, D.; Kim, N. J.; Yun, H.; Lee, S.; Chang, D. J.; Hong, H. S.; Kim, H.; Ha, H. J.; Kim, Y. H.; Park, H. J.; Lee, J.; Suh, Y. G. Ligand-based design, synthesis, and biological evaluation of 2-aminopyrimidines, a novel series of receptor for advanced glycation end products (RAGE) inhibitors J. Med. Chem. 2012, 55, 9120-9135 10.1021/jm300172z
125. Kim, S. H.; Han, Y. T. Design, synthesis, and biological evaluation of pyrimidine-2-carboxamide analogs: investigation for novel RAGE inhibitors with reduced hydrophobicity and toxicity Arch. Pharmacal Res. 2015, 38, 1952-1962 10.1007/s12272-015-0596-5
126. Han, Y. T.; Kim, K.; Son, D.; An, H.; Kim, H.; Lee, J.; Park, H. J.; Lee, J.; Suh, Y. G. Fine tuning of 4,6-bisphenyl-2-(3-alkoxyanilino)pyrimidine focusing on the activity-sensitive aminoalkoxy moiety for a therapeutically useful inhibitor of receptor for advanced glycation end products (RAGE) Bioorg. Med. Chem. 2015, 23, 579-587 10.1016/j.bmc.2014.12.003
127. Han, Y. T.; Kim, K.; Choi, G. I.; An, H.; Son, D.; Kim, H.; Ha, H. J.; Son, J. H.; Chung, S. J.; Park, H. J.; Lee, J.; Suh, Y. G. Pyrazole-5-carboxamides, novel inhibitors of receptor for advanced glycation end products (RAGE) Eur. J. Med. Chem. 2014, 79, 128-142 10.1016/j.ejmech.2014.03.072
128. Choi, K.; Lim, K. S.; Shin, J.; Kim, S. H.; Suh, Y. G.; Hong, H. S.; Kim, H.; Ha, H. J.; Kim, Y. H.; Lee, J.; Lee, J. 6-Phenoxy-2-phenylbenzoxazoles, novel inhibitors of receptor for advanced glycation end products (RAGE) Bioorg. Med. Chem. 2015, 23, 4919-4935 10.1016/j.bmc.2015.05.022
129. Mjalli, A. M. M.; Andrews, R. C.; Gopalaswamy, R.; Wysong, C. Carboxamide Derivatives as Therapeutic Agents. WO2002070473, 2002.
130. Mjalli, A. M. M.; Gopalaswamy, R.; Avor, K.; Wysong, C.; Patron, A. Method for the Synthesis of Compounds of Formula I and Their Uses Thereof. WO2001092210, 2002.
131. Mjalli, A. M. M.; Andrews, R. C.; Gopalaswamy, R.; Hari, A.; Avor, K.; Qabaja, G.; Guo, X. C.; Gupta, S.; Jones, D. R.; Chen, X. Mono- and Bicyclic Azole Derivatives that Inhibit the Interaction of Ligands with Rage. WO2003075921, 2003.
132. Mjalli, A. M. M.; Gopalaswamy, R. Benzimidazole Derivatives as Therapeutic Agents. WO2002069965, 2003.
133. Ross, N. T.; Deane, R.; Perry, S.; Miller, B. L. Structure-activity relationships of small molecule inhibitors of RAGE-Aβ binding Tetrahedron 2013, 69, 7653-7658 10.1016/j.tet.2013.05.079
134. Gu, Q.; Wang, B.; Zhang, X. F.; Ma, Y. P.; Liu, J. D.; Wang, X. Z. Contribution of receptor for advanced glycation end products to vasculature-protecting effects of exercise training in aged rats Eur. J. Pharmacol. 2014, 741, 186-194 10.1016/j.ejphar.2014.08.017
135. Cui, L.; Cai, Y.; Cheng, W.; Liu, G.; Zhao, J.; Cao, H.; Tao, H.; Wang, Y.; Yin, M.; Liu, T.; Liu, Y.; Huang, P.; Liu, Z.; Li, K.; Zhao, B. A Novel, Multi-Target Natural Drug Candidate, Matrine, Improves Cognitive Deficits in Alzheimer's Disease Transgenic Mice by Inhibiting Abeta Aggregation and Blocking the RAGE/Abeta Axis Mol. Neurobiol. 2017, 54, 1939-1952 10.1007/s12035-016-9783-8
136. Mizumoto, S.; Takahashi, J.; Sugahara, K. Receptor for advanced glycation end products (RAGE) functions as receptor for specific sulfated glycosaminoglycans, and anti-RAGE antibody or sulfated glycosaminoglycans delivered in vivo inhibit pulmonary metastasis of tumor cells J. Biol. Chem. 2012, 287, 18985-18994 10.1074/jbc.M111.313437
137. Zhang, J.; Xu, X.; Rao, N. V.; Argyle, B.; McCoard, L.; Rusho, W. J.; Kennedy, T. P.; Prestwich, G. D.; Krueger, G. Novel sulfated polysaccharides disrupt cathelicidins, inhibit RAGE and reduce cutaneous inflammation in a mouse model of rosacea PLoS One 2011, 6, e16658 10.1371/journal.pone.0016658
138. Arumugam, T.; Ramachandran, V.; Gomez, S. B.; Schmidt, A. M.; Logsdon, C. D. S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis Clin. Cancer Res. 2012, 18, 4356-4364 10.1158/1078-0432.CCR-12-0221
139. Schmidt, A. M.; Ramasamy, R.; Shekhtman, A.; Rai, V.; Manigrasso, M. B. Amido and Heterocyclic Compounds as Modulators of Rage Activity and Uses Thereof. WO2015050984, 2014.
140. Kim, S. J.; Ahn, J. W.; Kim, H.; Ha, H. J.; Lee, S. W.; Kim, H. K.; Lee, S.; Hong, H. S.; Kim, Y. H.; Choi, C. Y. Two beta-strands of RAGE participate in the recognition and transport of amyloid-beta peptide across the blood brain barrier Biochem. Biophys. Res. Commun. 2013, 439, 252-257 10.1016/j.bbrc.2013.08.047
141. Mohan, S. K.; Gupta, A. A.; Yu, C. Interaction of the S100A6 mutant (C3S) with the V domain of the receptor for advanced glycation end products (RAGE) Biochem. Biophys. Res. Commun. 2013, 434, 328-333 10.1016/j.bbrc.2013.03.049
142. Yatime, L.; Betzer, C.; Jensen, R. K.; Mortensen, S.; Jensen, P. H.; Andersen, G. R. The Structure of the RAGE:S100A6 Complex Reveals a Unique Mode of Homodimerization for S100 Proteins Structure 2016, 24, 2043-2052 10.1016/j.str.2016.09.011
143. Jones, D.; Gowda, R. B.; Xie, R. Substituted Imidazole Derivatives for Treatment of Alzheimers Disease. WO2011041198, 2012.
144. Mjalli, A. M. M.; Andrews, R. C.; Shen, J. M.; Rothlein, R. Rage Antagonists as Agents to Reverse Amyloidosis and Diseases Associated Therewith. WO2005000295, 2009.